Aerogen, the Ireland-based global leader in acute-care aerosol drug delivery, has announced the opening of its India headquarters in the National Capital Territory of Delhi. The new office was officially inaugurated by Ireland’s Minister for Higher Education, Research, and Innovation, James Lawless, during his visit to India on the occasion of Ireland’s National Day – St. Patrick’s Day. This strategic expansion underscores Aerogen’s commitment to supporting India’s growing healthcare sector by improving access to cutting-edge aerosol drug delivery solutions.
With over 55 million people in India suffering from chronic obstructive pulmonary disease and a significant burden of respiratory diseases, Aerogen’s innovative vibrating mesh nebuliser technology is set to play a transformative role in enhancing patient outcomes. Already the standard of care in Europe and the USA, Aerogen’s drug delivery system is now poised to support Indian healthcare providers in delivering high-quality respiratory care.
Speaking at the inauguration, Hon. Minister James Lawless emphasized the significance of Aerogen’s expansion and the broader collaboration between India and Ireland, stated, “This milestone strengthens the ties between India and Ireland, reinforcing our shared commitment to healthcare innovation. Aerogen’s decision to establish its presence in India is a testament to the country’s rapidly advancing healthcare ecosystem. We look forward to fostering a borderless enterprise where bilateral collaboration in innovation and research benefits both India and Ireland.”
The opening of the India headquarters represents a major investment in the APAC region and reinforces Aerogen’s long-term vision for India. The new office in New Delhi will serve as the operational hub for a growing team of experts, including a country director, marketing professionals, commercial sales specialists, and clinical experts. Starting with 14 team members, Aerogen plans to expand to 30 employees over the next five years to support its growth and market penetration.
Highlighting Aerogen’s commitment to India, Hannah Yuill, Senior Commercial Director APAC said, “Aerogen is dedicated to ensuring that hospitals and patients in India have access to the most advanced aerosol drug delivery systems. With India’s large population and the increasing prevalence of respiratory diseases, our expansion is a crucial step in supporting the healthcare system in delivering superior patient care safely and effectively. This investment in India is a vital part of our strategy to expand across the APAC region and collaborate closely with healthcare professionals to improve respiratory treatment outcomes.”
Designed to foster innovation and collaboration, the India headquarters features state-of-the-art meeting rooms, private offices, a reception area, a library, a gym and yoga space, a recreation zone, and a landscaped lawn, providing a dynamic and inspiring workspace for the team.
Aerogen’s India expansion is a reflection of the robust economic ties between Ireland and India. The company’s global growth has been supported by Enterprise Ireland, the Irish government agency that helps Irish businesses scale internationally.
Ross Curran, Director – India & South Asia, Enterprise Ireland, added, “Ireland is a global leader in medtech innovation, and Aerogen is at the forefront of this advancement. Their expansion in India highlights not only
their commitment to enhancing respiratory care worldwide but also the deepening economic and business collaborations between Ireland and India. We are proud to support Aerogen’s journey in making a lasting impact on global healthcare.”
Aerogen’s presence in India is set to drive investment in research, partnerships, and training programs to ensure the widespread adoption of its advanced aerosol drug delivery technology. By collaborating with leading clinicians, hospitals, and channel partners across India and Sri Lanka, Aerogen is positioned to revolutionize respiratory care, ultimately improving patient outcomes and strengthening the country’s healthcare infrastructure.